Generic weight loss drugs boosted by UK approval for Biocon

Biocon is betting on anti-obesity therapies as patents for the blockbuster drugs begin to expire, sparking a wave of generic supply for a global weight-loss market expected to touch USD 100bn by 2030.
Photo: Abhishek Chinnappa/Reuters/Ritzau Scanpix
Photo: Abhishek Chinnappa/Reuters/Ritzau Scanpix
By Satviki Sanjay and Advait Palepu, Bloomberg

The Bengaluru-based firm, that has been churning out off-patient medicines treating diabetes, scored an early win with the UK approval for the first generic version of liraglutide injectable, whose patent ends in November. 

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading